Pneumonia due to Pseudomonas aeruginosa: The levofloxacin clinical trials experience

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 843-850

  Tennenberg, Alan M ^a   Davis, Neelam B ^b   Wu, Shu Chen ^b   Kahn, James ^b  

^a Tibotec Therapeutics   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Clinical efficacy; Community acquired pneumonia; Nosocomial pneumonia; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME AXETIL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; OFLOXACIN; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33745028154     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X100195     Document Type: Article

References (44)

1. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin Infect Dis 1998;27(Suppl 1):S93-S99
2. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerase II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist 2003;9:323-8
3. Le Thomas I, Couetdic G, Clermont O, et al. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001;48:553-5
4. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8
5. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82
6. NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32
7. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85
8. Fagon J-Y, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8
9. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-20
10. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998;2:211-5
11. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621-9
12. Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-29
13. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38(Suppl 1):S16-S23
14. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20
15. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505
16. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. J Am Med Assoc 1996;275:134-41
17. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58
18. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;25:485-506
19. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002;35:381-9
20. Klimberg IW, Cox II CE, Fowler CL, et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998;51:610-5
21. Richard GA, Childs SJ, Fowler CL, et al. Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharm Ther 1998;23:534-40
22. Thornsberry C, Karlowsky JA, Weaver MK, et al. Current view of antimicrobial susceptibility among bacterial pathogens that commonly cause nosocomial pneumonia: 2003 TRUST surveillance study. Presented at the Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003
23. Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005;40 (Suppl 2):S89-S98
24. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114-22
25. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7
26. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-85
27. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 2001;21:302S-18S
28. Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998;42:953-5
29. MacGowan AP, Wootton M, Holt HA. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999;43:345-9
30. Burgess DS, Nathisuwan S. Cefepime, pipericillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002;44:35-41
31. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003;46:131-7
32. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005;40(Suppl 2):S105-S114
33. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002;22:1216-25
34. Wiesinger BA, Noel GJ, Tennenberg AM, Kahn JB. The safety of high-dose (750-mg qd) levofloxacin. Presented at the 10th International Conference on Infectious Diseases, Singapore, 2002
35. Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-9
36. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-57
37. Coyle EA, Lewis RE, Chi J, et al. Varying doses of levofloxacin (LV) and the corresponding relationship of antimicrobial activity and resistance selection against Pseudomonas aeruginosa (PA). Presented at the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002 [abstract A-1207]
38. Garrison MW. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2006;54:51-6
39. Burgess DS, Hall II RG. Levofloxacin low dose (500 mg) and high dose (750 mg) alone and in combination against P. aeruginosa. Pharmacotherapy 2002;22:413
40. File Jr TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72
41. Fogarty CM, Sullivan JG, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998;7:400-7
42. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-308
43. Akpunonu B, Michaelis J, Tennenberg A, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004;38(Suppl 1):S5-S15
44. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60